公开(公告)号：US07033994B2

公开(公告)日：2006-04-25

申请号：US10168727

申请日：2000-12-21

申请人： Tatsuya Araki ,  Kazuhiko Tomokiyo ,  Yasushi Nakatomi ,  Kaori Teshima ,  Tomoko Watanabe ,  Tomohiro Nakagaki

发明人： Tatsuya Araki ,  Kazuhiko Tomokiyo ,  Yasushi Nakatomi ,  Kaori Teshima ,  Tomoko Watanabe ,  Tomohiro Nakagaki

IPC分类号： A61K38/00 ,  A61K35/14 ,  A61K35/16

CPC分类号： A61K38/37 ,  Y10S514/802 ,  Y10S514/834

摘要： The present invention provides a pharmaceutical composition for treatment and prevention of bleeding disorders caused by platelet disorders, not caused by defect in blood coagulation factors or von Willebrand Factor but caused by reduction of circulating platelet count or platelet dysfunction, said composition comprising a hemostatic effective amount of Factor VIII and/or von Willebrand Factor. Also provided is a method for treating said bleeding, comprising administering a hemostatic effective amount of Factor VIII and/or von Willebrand Factor to patients suffering from bleeding disorders caused by platelet disorders.

公开(公告)号：US06881721B2

公开(公告)日：2005-04-19

申请号：US10168371

申请日：2000-12-21

申请人： Yasushi Nakatomi ,  Kazuhiko Tomokiyo ,  Tatsuya Araki ,  Kaori Teshima ,  Tomoko Watanabe ,  Tomohiro Nakagaki

发明人： Yasushi Nakatomi ,  Kazuhiko Tomokiyo ,  Tatsuya Araki ,  Kaori Teshima ,  Tomoko Watanabe ,  Tomohiro Nakagaki

IPC分类号： A61K38/43 ,  A61K38/48 ,  A61P7/04 ,  A61K38/00

CPC分类号： A61K38/4846

摘要： The present invention provides a pharmaceutical composition for treatment and prevention of hemorrhage associated with blood coagulation disorders, comprising activated Factor VII (FVIIa) and Factor X (FX) as an active ingredient. The pharmaceutical composition of the present invention contains no components causative side effects, is safe, highly efficacious, and easy to manage hemostasis. The pharmaceutical composition can be used for hemostatic management of patients suffering from hemorrhage associated with blood coagulation disorders, for example, disorders (including deficiency) of blood coagulation factors, especially caused by inhibitors (antibodies) against blood coagulation factors.

摘要翻译： 本发明提供了用于治疗和预防与凝血障碍相关的出血的药物组合物，其包含活化因子VII（FVIIa）和因子X（FX）作为活性成分。 本发明的药物组合物不含成分副作用，安全，高效，易于止血。 药物组合物可以用于与血液凝固障碍相关的出血患者的止血管理，例如血液凝固因子的紊乱（包括缺乏），特别是由针对凝血因子的抑制剂（抗体）引起的。

公开(公告)号：US07329724B2

公开(公告)日：2008-02-12

申请号：US10483427

申请日：2002-07-10

申请人： Tatsuya Araki ,  Kazuhiko Tomokiyo ,  Yasushi Nakatomi ,  Kaori Teshima ,  Tomohiro Nakagaki

发明人： Tatsuya Araki ,  Kazuhiko Tomokiyo ,  Yasushi Nakatomi ,  Kaori Teshima ,  Tomohiro Nakagaki

IPC分类号： A61K38/00

CPC分类号： A61K9/0019 ,  A61K9/19 ,  A61K38/4846 ,  A61L24/108 ,  A61L2400/04

摘要： A novel hemostatic composition and a hemostatic pharmaceutical preparation are provided. A pharmaceutically stable hemostatic liquid composition comprising a mixed solution of activated blood coagulation factor VII (FVIIa) and blood coagulation factor X (FX) in a single container. The mixed solution is maintained at pH ranging from 5.0 to 6.5.

摘要翻译： 提供了一种新型止血组合物和止血药物制剂。 一种药物稳定的止血液体组合物，其包含活化凝血因子VII（FVIIa）和凝血因子X（FX）在单个容器中的混合溶液。 将混合溶液保持在5.0至6.5的pH。